Impact of the delisting of the FFR on our practices, medico-economic evaluation

Project summary

CONTEXT

The delisting of the FFR has been effective since March 31, 2023 for economic reasons against the advice of cardiologists.

GOALS

Evaluate the impact of this dereimbursement measure on the use of FFR and the consumption of stents before and after

METHODOLOGY

Descriptive analysis of the study population in 2 periods (Reimbursement from January 1 to March 31 and reimbursement - from April 1 to June 29):

Number of diagnostic procedures and angioplasties as well as the number of FFRs during these two periods.

Analysis of medical economic cost.